HIV Infections Clinical Trial
Official title:
Liberia School-Based HIV/STD Prevention Program
This study will evaluate the effectiveness of a school-based HIV/sexually transmitted disease prevention program in reducing sexual risk behaviors of youth attending school in Liberia.
Currently, more than 60 million people have been diagnosed with HIV/AIDS worldwide. It is
estimated that about two-thirds of all HIV infections are among people in Africa. The
African country of Liberia, in particular, is experiencing an increase in HIV/sexually
transmitted disease (STD) infections and is in need of improved HIV/STD-related prevention
programs. With the majority of the new infections occurring among people who are between 15
and 29 years old, new HIV/STD prevention programs are needed to educate youth about proper
condom use and risks associated with sexual behaviors. Previous research has suggested that
behavioral interventions can reduce adolescents' sexual behaviors that are tied to risk of
acquiring STDs. The evidenced-based HIV prevention program, Making Proud Choices, is an
intervention originally designed for community settings in the United States, but is
currently being adapted in schools of certain sub-Saharan African countries. Adapting this
community-based curriculum to school-based settings and cultural contexts within Liberia may
be effective in reducing risky sexual behaviors in Liberian adolescents. This study will
compare the effectiveness of a school-based HIV/STD prevention program that draws on the
curriculum of Making Proud Choices versus a general health promotion program in reducing
sexual risk behaviors of youth attending school in Liberia.
Participation in this study will involve two phases. Phase 1 will last 8 months and will be
used to adapt the community-based curriculum of Making Proud Choices to school-based
settings and contexts within Liberia. Data to guide the integration and cultural adaptation
of the curriculum will be collected from school administrators, students, health educators,
and community-based organizations through focus groups, group discussions, and interviews.
Phase 2 will last about 12 months and will include junior high schools in Liberia.
Participating schools will be assigned randomly to provide the adapted HIV prevention
curriculum or a general health promotion curriculum. Before starting course modules,
students receiving either curriculum will complete questionnaires about their
risk-associated sexual behaviors and knowledge about condom use and abstinence. Both
curriculums will include eight 1-hour modules delivered weekly over 8 weeks. The HIV
prevention curriculum will focus on increasing knowledge about preventing HIV, STDs, and
pregnancy; improving condom use skills; increasing confidence in the ability to negotiate
safer sex and to use condoms correctly; and lowering the incidence of sexual-risk behavior.
The general health promotion curriculum will focus on teaching students healthful behaviors,
including eating habits, physical activity, dental hygiene, and avoidance of cigarette
smoking and substance abuse. All participants will repeat the initial questionnaires
immediately after completing the curriculum and 3, 6, and 9 months after the curriculum
ends.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |